This research was planned to determine the level of nesfatin-1, known as satiety hormone, in type 2 diabetes, insulin diabetes and obesity patients and to determine whether there is a relationship between patients' energy intake levels. Additionally, it was aimed to evaluate the relationship between patients' nesfatin-1 values and serum glucose, insulin, lipid concentrations.
Nesfatin-1 levels of patients with type 2 diabetes, insulin resistance and obesity will be measured. In addition, patients' daily food consumption will be taken and the amount of energy they receive will be calculated daily. The relationship between the level of nesfatin-1 in the blood and the energy received will be examined.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
TRIPLE
Enrollment
180
Blood will be taken from the patients on an empty stomach for measuring nesfatin-1 level
Haydarpaşa Numune Education and Research Hospital
Istanbul, Turkey (Türkiye)
RECRUITINGNefratin-1 in type 2 diabetes
Blood will be drawn from type 2 diabates patients after 12 hours of fasting (n=45)
Time frame: 1 day (Blood will be drawn from patients once)
Nefratin-1 in obesity
Blood will be drawn from obesity patients after 12 hours of fasting (n=45)
Time frame: 1 day (Blood will be drawn from patients once)
Nefratin-1 in insulin resistance
Blood will be drawn from insulin resistance patients after 12 hours of fasting (n=45)
Time frame: 1 day (Blood will be drawn from patients once)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.